 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3 clinical study of omidubicel presented in an oral session at the Transplantation Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy ASTCT and Center for International Blood Marrow Transplant Research CIBMTR, or the TCT Meetings. Omidubicel i 